Application of nervonic acid in preparation of medicine for preventing and treating psoriasis

By using nerucic acid in psoriatic drugs, the epidermal thickness and dermal lymphocyte infiltration have been reduced, and the side effects and long-term use of existing therapeutic drugs have been solved, and effective prevention and treatment of psoriasis has been achieved. It is suitable for different types of silver Sarcopenia.

CN118903091AActive Publication Date: 2024-11-08XINXIANG MEDICAL UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410809098.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-21
Publication Date
2024-11-08
Estimated Expiration
2044-06-21

AI Technical Summary

Technical Problem

Drugs for treating psoriasis often lead to serious side effects, and existing drugs are not suitable for long-term use, and the course of psoriasis is long and recurrent, affecting the quality of life of patients.

Method used

Neuric acid is used as an active ingredient, and by reducing epidermal thickness, dermal lymphocyte infiltration and cytokeratosis, the concentration is controlled between 5% and 15% as a drug to prevent and treat psoriasis, to alleviate the symptoms of psoriasis, including pus blister, joint type, vulgaris and erythroderma psoriasis.

Benefits of technology

It significantly reduces the symptoms of psoriasis, including reducing epidermal thickening, dermal lymphocyte infiltration and cytokeratosis. As a new drug to resist the development of psoriasis, it has good prevention and treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903091A_ABST
    Figure CN118903091A_ABST
Patent Text Reader

Abstract

The invention discloses application of nervonic acid in preparation of a medicine for preventing and treating psoriasis, and relates to the technical field of medicines. The nervonic acid is adopted as an active ingredient in the medicine for preventing and treating the psoriasis, so that a good prevention and treatment effect is shown in a psoriasis treatment model, epidermis thickening of a psoriasis affected part can be reduced, dermis lymphocyte infiltration of the psoriasis affected part can be reduced, incomplete cell keratosis of the psoriasis affected part can be reduced, erythema of the psoriasis affected part can be relieved, and the psoriasis treatment effect can be improved. The compound can be used as a new medicine for resisting psoriasis development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an application of neuraminic acid in the preparation of a drug for preventing and treating psoriasis. Background Art

[0002] Psoriasis is an immune-mediated chronic inflammatory systemic disease characterized by keratinocyte hyperplasia, inflammatory cell infiltration and dermal vascular hyperplasia. The incidence in my country is about 0.5%, and there is still a trend of continuous increase. Psoriasis has a long course of disease, and repeated attacks and prolonged illness bring huge mental and psychological burdens and economic pressures to patients, greatly affecting the quality of life of patients. In addition, some patients with psoriasis may have various complications, such as hyperlipidemia, cardiovascular disease, diabetes and cancer, among which cardiovascular and metabolic diseases are the most common comorbidities of psoriasis. Psoriasis patients are usually treated with glucocorticoids or conventional immunosuppressants, which can temporarily relieve symptoms but can cause serious side effects, such as atherosclerosis and adrenal insufficiency; in addition, drugs such as succubitus, although they have good efficacy in the treatment of psoriasis, are expensive and not suitable for long-term treatment of psoriasis.

[0003] In view of this, the present invention is proposed. Summary of the invention

[0004] The purpose of the present invention is to provide an application of neuraminic acid in the preparation of drugs for preventing and treating psoriasis.

[0005] The present invention is achieved in that:

[0006] In a first aspect, the present invention provides a use of neuraminic acid in the preparation of a drug for preventing and treating psoriasis.

[0007] Optionally, the concentration of nervonic acid is 5% to 15%.

[0008] Optionally, the concentration of nervonic acid is 5% to 10%.

[0009] Optionally, preventing and treating psoriasis comprises at least one of reducing the thickness of the epidermis in the psoriasis-affected area, reducing the infiltration of lymphocytes in the dermis, and reducing parakeratosis of epidermal cells.

[0010] Optionally, reducing the thickness of the epidermis in a psoriasis-affected area is reducing the thickness of the stratum spinosum.

[0011] Optionally, the drug consists of neuraminic acid and a pharmaceutically acceptable carrier.

[0012] Optionally, the drug is for external use.

[0013] Optionally, the dosage form of the drug includes any one of lotion, ointment, patch, film coating, gel, microneedle, aerosol or spray.

[0014] Optionally, the medication includes petrolatum and nervonic acid.

[0015] Optionally, sources of neuraminic acid include Acer truncatum seed oil or other animal or plant materials containing neuraminic acid.

[0016] Optionally, psoriasis includes any one of pustular psoriasis, articular psoriasis, psoriasis vulgaris, or erythrodermic psoriasis.

[0017] The present invention has the following beneficial effects:

[0018] The present invention provides an application of neuraminic acid in the preparation of a drug for preventing and treating psoriasis. By adopting neuraminic acid as an active ingredient in the drug for preventing and treating psoriasis, a good prevention and treatment effect is shown in a psoriasis treatment model, and the neuraminic acid can reduce the epidermal thickening of the psoriasis-affected area, reduce the dermal lymphocyte infiltration of the psoriasis-affected area, reduce the cell parakeratosis of the psoriasis-affected area, and alleviate the erythema of the psoriasis-affected area. The neuraminic acid can be used as a new drug for resisting the development of psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0020] Figure 1 The back skin status of mice in different groups on the sixth day of modeling provided in Example 1 of the present invention;

[0021] Figure 2 This is a PASI erythema scoring diagram during the modeling process provided in Example 1 of the present invention;

[0022] Figure 3 The PASI scaling score diagram during the modeling process provided in Example 1 of the present invention;

[0023] Figure 4 This is a PASI dermal cell infiltration scoring diagram during the modeling process provided in Example 1 of the present invention;

[0024] Figure 5 A graph showing the total PASI score during the modeling process provided in Example 1 of the present invention;

[0025] Figure 6 This is a graph showing changes in mouse weight during the modeling process provided in Example 1 of the present invention;

[0026] Figure 7This is an optical microscopic image of the mouse skin tissue after HE staining provided in Example 1 of the present invention;

[0027] Figure 8 This is a diagram showing the effects of different cell culture methods provided in Example 2 of the present invention on the expression of chemokines and inflammatory factors. DETAILED DESCRIPTION

[0028] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0029] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0030] In a first aspect, the present invention provides a use of neuraminic acid in the preparation of a drug for preventing and treating psoriasis.

[0031] Nervonic acid (NA) is a special unsaturated fatty acid. It is rich in the new food resource Acer truncatum seed oil and plays an important role in human health, especially the development of the brain. Nervonic acid deficiency will cause brain diseases such as stroke sequelae, Alzheimer's disease, cerebral palsy, brain atrophy, memory loss, insomnia and forgetfulness. Nervonic acid has high medicinal value and unique neurological health care effects. It can especially promote the repair of damaged brains and improve memory. In recent years, it has attracted much attention as an important health product.

[0032] However, the inventor's research shows that neuraminic acid has an unexpected preventive and therapeutic effect in the field of psoriasis prevention and treatment. Neuroacid mainly maintains the composition, structure and function of biological membranes through sphingomyelin and sphingolipids, thereby improving cell vitality and enhancing human functions, thereby exerting anti-inflammatory activity. Therefore, the inventor uses neuraminic acid as an active ingredient in drugs for the prevention and treatment of psoriasis, thereby reducing epidermal thickening in psoriasis-affected areas, reducing dermal lymphocyte infiltration in psoriasis-affected areas, reducing cell parakeratosis in psoriasis-affected areas, and reducing erythema in psoriasis-affected areas. Therefore, neuraminic acid can be used as a new drug to resist the development of psoriasis.

[0033] In an optional embodiment, the concentration of neuraminic acid is 5% to 15%, for example, it can be any value among 5%, 7%, 9%, 11%, 13% or 15%, or a range value between any two values.

[0034] Preferably, the concentration of neuraminic acid is 5% to 10%, for example, it can be any value among 5%, 6%, 7%, 8%, 9% or 10%, or a range value between any two values.

[0035] As an active ingredient for the prevention and treatment of psoriasis, neuraminic acid can effectively alleviate the specific symptoms of psoriasis, such as epidermal thickening, parakeratosis of epidermal cells, and lymphocyte infiltration in the dermis. However, controlling the concentration of neuraminic acid within the above-mentioned range will help improve the prevention and treatment effect of psoriasis.

[0036] In an optional embodiment, preventing and treating psoriasis includes at least one of reducing the thickness of the epidermis in the psoriasis-affected area, reducing the lymphocyte infiltration in the dermis, and reducing the parakeratosis of epidermal cells.

[0037] In an optional embodiment, reducing the thickness of the epidermis in the psoriasis affected area is to reduce the thickness of the stratum spinosum. Psoriasis stimulates the continuous proliferation of basal cells, resulting in an increase in the number of spinous cells in the stratum spinosum, which leads to thickening of the stratum spinosum. More spinous cells will increase the frequency of keratinocyte renewal and shedding, thereby increasing the amount of flaky or semi-shedding keratin. By using neuraminic acid to prevent and treat psoriasis, the thickness of the stratum spinosum can be reduced, thereby alleviating the symptoms of psoriasis.

[0038] In an optional embodiment, the drug consists of neuraminic acid and a pharmaceutically acceptable carrier.

[0039] In an alternative embodiment, the drug is an external medicine.

[0040] In an optional embodiment, the dosage form of the drug includes any one of a lotion, an ointment, a patch, a film coating, a gel, a microneedle, an aerosol or a spray.

[0041] In an optional embodiment, the drug includes vaseline and nervonic acid. Vaseline, as a carrier of nervonic acid, is not only conducive to the storage and transportation of the drug, but also convenient for coating and use.

[0042] In order to ensure that neuraminic acid is evenly dispersed, when preparing neuraminic acid drugs, it should be added to vaseline in small amounts and multiple times. After the neuraminic acid is evenly dispersed each time, a certain amount of neuraminic acid should be added to disperse it again.

[0043] In an optional embodiment, the source of neuraminic acid includes Acer truncatum seed oil or other animal or plant materials containing neuraminic acid.

[0044] In alternative embodiments, psoriasis includes any of pustular psoriasis, articular psoriasis, psoriasis vulgaris, or erythrodermic psoriasis.

[0045] Example 1

[0046] This embodiment provides an application of neuraminic acid in the preparation of a drug for preventing and treating psoriasis, as follows:

[0047] S01. Preparation of drugs for preventing and treating psoriasis

[0048] Weigh 50 mg of neuraminic acid powder and dissolve it in 1 g of vaseline. Add the neuraminic acid powder into the vaseline in small amounts and several times, and keep stirring thoroughly during the adding process until the ointment has no powdery particles on the surface and has a uniform color. To prepare an ointment with a concentration of 5% of neuraminic acid as the active ingredient (hereinafter referred to as 5% NA ointment).

[0049] Weigh 100 mg of neuraminic acid powder and dissolve it in 1 g of vaseline. Add the neuraminic acid powder into the vaseline in small amounts and several times, and keep stirring thoroughly during the adding process until the ointment has no powdery particles on the surface and has a uniform color. To prepare an ointment with a concentration of 10% of neuraminic acid as the active ingredient (hereinafter referred to as 10% NA ointment).

[0050] Among them, neuraminic acid powder was purchased from MedChemExpress LLC in the United States, and vaseline was purchased from Haishi Hainuo Group Co., Ltd.

[0051] S02. Induction of psoriasis model and prevention and treatment of psoriasis

[0052] The experimental mice were female Balb / c mice (SPF grade, 8 weeks old, weighing about 20 g) purchased from Beijing Sibeifu Company, and the animal study was approved by the Ethics Committee of Xinxiang Medical College.

[0053] Balb / c mice with basically the same growth conditions were raised at a temperature of 24±2°C, a humidity of 40-50%, a light / dark cycle of 12h and pathogen-free conditions, and were given sufficient food and water. After one week of feeding, the Balb / c mice were randomly divided into four groups (control group, vaseline group, 5% NA group and 10% NA group), with five mice in each group. The back of the mice was depilated one day before modeling, and the depilated area was 2×2.5cm.

[0054] Starting from the day of modeling, 62.5 mg of imiquimod (IMQ) cream was applied to the depilatory areas on the backs of the four groups of Balb / c mice at 9 am every day, and 62.5 mg of vaseline was applied to the depilatory areas on the backs of the vaseline group at 13:00 every day, 62.5 mg of 5% NA ointment was applied to the depilatory areas on the backs of the 5% NA group, 62.5 mg of 10% NA ointment was applied to the depilatory areas on the backs of the 10% NA group, and the control group did not receive any treatment for six consecutive days.

[0055] Among them, imiquimod (IMQ) was purchased from Sichuan Mingxin Pharmaceutical Co., Ltd.

[0056] S03. Experimental Results

[0057] S031. Photographing the back skin phenotype of Balb / c mice: Starting from the day of modeling, the back skin of each group of Balb / c mice was photographed at the same time point every day before applying imiquimod. The back skin status of Balb / c mice photographed before applying imiquimod on the day of modeling was the blank group. The back skin status of Balb / c mice on the sixth day of modeling was compared with the blank group to obtain the following results: Figure 1 Results shown.

[0058] Depend on Figure 1 It can be seen that the back skin of the four groups of Balb / c mice showed different degrees of psoriasis symptoms compared with the blank group, such as increased epidermal dandruff, rough and cracked skin, etc., indicating that imiquimod-induced psoriasis symptoms have occurred.

[0059] Among them, the control group did not take any preventive measures, so the back skin was severely damaged and had the most scales. The vaseline group used vaseline to moisturize the skin, but it had no therapeutic effect on psoriasis, so the skin damage in the vaseline group was not alleviated, and only a partial moisturizing effect was achieved. The 5% NA group showed a state of reduced psoriasis symptoms, with less psoriasis, less erythema, and less local infiltration compared to the control group. The 10% NA group showed significantly reduced psoriasis symptoms compared to the control group, with significantly less skin psoriasis, significantly less erythema, and significantly less local infiltration in the mice in this group.

[0060] The phenotypic changes of the back skin of Balb / c mice taken during the six-day modeling were statistically analyzed and the PASI score was calculated. Figure 2 to Figure 5 Results shown.

[0061] The PASI score includes erythema score, scaling score and skin thickness score of the skin lesions of Balb / c mice, and the sum of the above scores is calculated. The scoring criteria are as follows:

[0062] Erythema score: 0 = none; 1 = mild; 2 = marked; 3 = severe; 4 = very severe.

[0063] Scaling score: 0 = none; 1 = mild; 2 = marked; 3 = severe; 4 = very severe.

[0064] Skin thickness: 0 = none; 1 = slight; 2 = marked; 3 = severe; 4 = very severe.

[0065] Depend on Figure 2 to Figure 5 It can be seen that both the 5% NA group and the 10% NA group showed good effects in alleviating psoriasis symptoms, and the erythema score, scaling score and skin thickness score were improved to varying degrees compared with the control group.

[0066] S032. Body weight determination of Balb / c mice: Starting from the day of modeling, the body weight of Balb / c mice was measured and recorded at the same time point before applying imiquimod every day. After the experiment, the weight changes of all mice were counted to obtain the following: Figure 3 Results shown.

[0067] Depend on Figure 6 It can be seen that the weight loss of mice in the 5% NA group and the 10% NA group was lower than that in the control group. It is understandable that when psoriasis symptoms appear, the mice may be affected to varying degrees physically and psychologically due to the degree of psoriasis symptoms, which may indirectly affect appetite or motivation, etc. The present invention uses neuraminic acid to treat imiquimod-induced mice. The 5% NA group and the 10% NA group had a lower weight loss than the control group. Figure 1 to Figure 5 The effects shown show that it has a significant effect on alleviating psoriasis symptoms, and therefore the impact on the weight of mice is smaller than that of the control group.

[0068] S033. After the modeling was completed, the mice were killed, and the mouse skin tissue of about 0.5×0.5 cm in length was cut and fixed in 4% paraformaldehyde solution; paraffin embedding method was used for tissue sectioning (5 μm longitudinal section); H&E staining (dewaxing, gradient rehydration, hematoxylin nuclear staining, hydrochloric acid alcohol decolorization, eosin cytoplasm staining) was performed after dewaxing; after neutral resin sealing, the pathological histological changes were observed under an optical microscope and photographed, and the following were obtained: Figure 7 Results shown.

[0069] Depend on Figure 7 It can be seen that the skin of the four groups of mice showed psoriasis-like phenotypes such as epidermal thickening, incomplete keratinization of epidermal cells, thickening of the stratum spinosum and dermal lymphocyte infiltration. However, the stratum spinosum thickness of the 5% NA group and the 10% NA group was smaller than that of the control group, the number of incomplete keratinized epidermal cells decreased, and the dermal lymphocyte infiltration decreased, indicating that neuraminic acid has a good effect in preventing and treating psoriasis and can be used as an active ingredient in drugs for preventing and treating psoriasis.

[0070] Example 2

[0071] This embodiment provides an application of neuraminic acid in the preparation of a drug for preventing and treating psoriasis, as follows:

[0072] Blank group (control): HaCat cells (human immortalized keratinocytes) were plated in six-well plates and cultured in complete culture medium (89% DMEM medium + 10% FBS + 1% double antibody) for 5 hours. After the culture was completed, RNA was extracted and the expression of chemokines and inflammatory factors including CXCL1, CCL20 and S100A9 was detected. Figure 8 Results shown.

[0073] IL-17 group: HACAT cells were plated in six-well plates and placed in complete medium containing IL-17A at a concentration of 50 μg / ml for three hours. RNA was extracted and the expression of chemokines and inflammatory factors including CXCL1, CCL20 and S100A9 was detected. Figure 8 Results shown.

[0074] In the NA+IL-17 group, HACAT cells were plated in six-well plates and placed in a medium containing 100 μmol / ml neuraminic acid for two hours. The medium was then discarded and replaced with complete medium containing 50 μg / ml IL-17A for three hours. RNA was extracted and the expression of chemokines and inflammatory factors including CXCL1, CCL20 and S100A9 was detected. Figure 8 Results shown.

[0075] Depend on Figure 8 It can be seen that NA+IL-17 showed a significant inhibitory effect on the expression of CXCL1, CCL20 and S100A9, indicating that neuraminic acid has obvious anti-inflammatory ability and has a better application value in the prevention and treatment of psoriasis.

[0076] Comparative Example 1

[0077] Based on the application of Example 1, a 20% NA ointment was prepared. The preparation method was the same as that of Example 1, except that the mass of nervonic acid was 200 mg. The 20% NA ointment was tested according to the method of Example 1 to verify the application effect of nervonic acid in the preparation of drugs for the prevention and treatment of psoriasis. Figure 1-7 Results shown.

[0078] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing a drug for preventing and treating psoriasis.

2. The use according to claim 1, characterized in that: The concentration of the nervonic acid is 5% to 15%.

3. The use according to claim 1, characterized in that: The concentration of the nervonic acid is 5% to 10%.

4. The use according to claim 1, characterized in that: The method for preventing and treating psoriasis comprises at least one of reducing the thickness of the epidermis in the psoriasis affected area, reducing the thickness of the stratum spinosum, reducing the lymphocyte infiltration in the dermis, and reducing the parakeratosis of epidermal cells.

5. The use according to claim 4, characterized in that: The reducing the thickness of the epidermis in the psoriasis affected area is reducing the thickness of the stratum spinosum.

6. The use according to claim 1, characterized in that: The drug consists of the neuraminic acid and a pharmaceutically acceptable carrier.

7. The use according to claim 1, characterized in that: The medicine is for external use.

8. The use according to claim 7, characterized in that: The dosage form of the drug includes any one of lotion, ointment, patch, film coating, gel, microneedle, aerosol or spray.

9. The use according to claim 1, characterized in that: The drug includes vaseline and the nervonic acid.

10. The use according to claim 1, characterized in that: The psoriasis includes any one of pustular psoriasis, articular psoriasis, psoriasis vulgaris or erythrodermic psoriasis.

Citation Information

Patent Citations

  • Compostions and methods for treating chronic inflammation and inflammatory diseases

    CN103391768A

  • Endogenous metabolite composition for preventing relapse of psoriasis

    CN114544783A

  • Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof

    US20170165280A1